Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Just-Evotec Biologics

Request full access

Life changing protein therapeutics

Seattle, United StatesFounded 2014Biotech & Life Sciences

About Just-Evotec Biologics

Just-Evotec Biologics operates as a contract development and manufacturing organization (CDMO) with a mission to expand global access to biotherapeutics. The company was founded in 2014 as Just Biotherapeutics, with Dr. James (Jim) Thomas as a co-founder and CEO. Dr. Thomas brought extensive experience from leadership roles at Amgen, Immunex, and Genentech, where he contributed to the advancement of major therapeutics like Enbrel and Repatha. His career has centered on developing technologies for large-scale manufacturing of recombinant proteins. Just Biotherapeutics initially received backing from investors including ARCH Venture Partners, Merck & Co., Lilly Asia Ventures, and the Bill & Melinda Gates Foundation, aligning with its goal to reduce the cost of protein therapeutics.

In a significant milestone, Hamburg-based Evotec SE acquired Just Biotherapeutics in July 2019 for a total consideration of up to $90 million. The acquisition integrated Just.Bio's biologics capabilities with Evotec's small molecule expertise, creating a comprehensive R&D and manufacturing partner for the pharmaceutical industry. Following the acquisition, Dr. Thomas joined Evotec's leadership as Global Head of Biotherapeutics and President of U.S. Operations. Now operating as a wholly-owned subsidiary of Evotec, the company serves a diverse client base, from biotech startups to large pharmaceutical companies and government organizations, offering solutions for discovery, development, and manufacturing of biologics.

The core of Just-Evotec Biologics' offering is its proprietary J.DESIGN technology platform. This integrated, data-driven system utilizes machine learning and artificial intelligence across the entire development lifecycle, from molecular design to manufacturing. The platform aims to accelerate development timelines, de-risk the process, and substantially lower production costs. A key component is its continuous manufacturing process, housed in modular, automated facilities known as J.PODs. These facilities are designed to be more flexible, cost-effective, and faster to build than traditional manufacturing plants. They enable highly intensified, continuous production of biologics at various scales, from clinical to commercial, within a single facility. The company operates J.POD facilities in Redmond, Washington, and Toulouse, France, providing a global manufacturing network. Business models are flexible, ranging from standard fee-for-service contracts to strategic partnerships and technology licensing, allowing partners to integrate the J.POD system into their own operations.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
605
Open positions
None listed
Dealroom signal
80.7/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Drug Development, Biotech and Pharma, Techbio, Hard Tech, proteomics, DT and LS, science-based
Business model
Manufacturing

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Dec 2025 $0 — Sandoz ↗
GRANT✓Other financing Oct 2020 $0 — Bill & Melinda Gates Foundation —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Just-Evotec Biologics website traffic

Latest recorded traffic for Just-Evotec Biologics is 670 monthly website visits, down 52.1% over the last three months. Just-Evotec Biologics's team grew 97.7% over the past year.

Latest monthly visits670 3-month web change-52.1% 1-year team growth+97.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Just-Evotec Biologics in the Seattle ecosystem

Live from Dealroom

The Just-Evotec Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Other known investors2 additional known investors

  • Evotec
  • Sandoz
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
8 countries with
team presence
🇺🇸 United States90.5%
🇫🇷 France8%
🇨🇳 China0.4%
🇸🇪 Sweden0.2%
🇬🇧 United Kingdom0.2%
Top 5 of 8 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Just-Evotec Biologics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Just-Evotec Biologics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.